Open AccessHormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel—an Indirect Comparison
Author(s) -
Pui San Tan,
Benjamin Haaland,
Alberto J. Montero,
Christos E. Kyriakopoulos,
Gilberto Lopes
Publication year - 2014
Publication title -
clinical medicine insights oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.601
H-Index - 26
ISSN - 1179-5549
DOI - 10.4137/cmo.s13671
Subject(s) - enzalutamide , abiraterone acetate , medicine , docetaxel , prostate cancer , oncology , hazard ratio , prostate specific antigen , urology , cancer , confidence interval , androgen deprivation therapy , androgen receptor
This study aims to make an indirect comparison between enzalutamide and abiraterone acetate for mCRPC post-docetaxel.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom